Clinical Trial Update: Rollover Study of BMS-354825 in Patients With CML and Ph+ALL [Phase 1, Phase 2]

View source ↗

Summary

Rollover study of BMS-354825 (dasatinib) in patients with chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia has com…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelogenous Leukemia
• Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia

Drugs mentioned

• Sprycel (dasatinib) (dasatinib)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Chronic Myelogenous Leukemia, Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2010-12-14